Search





Search





Markets
/
Stocks
/
nasdaq-lnth
/

Lantheus Holdings Inc

LNTH

Add to Watchlist

103.800USD

-2.400-2.26%

Close 06/22, 16:00（ET）Quotes delayed by 15 min

6.75BMarket Cap

24.55P/E TTM

Lantheus Holdings Inc

103.800

-2.400-2.26%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey 图表

Intraday

30m

Today

-2.26%

5 Days

-0.83%

1 Month

+0.78%

6 Months

+52.62%

Year to Date

+55.97%

1 Year

+31.08%

Key Figures

104.470Open

106.625High

1.45KVolume

24.55P/E TTM

15.55P/E Dynamic

--Dividend TTM

0.00%Turnover Ratio

106.200Prev. Close

103.485Low

10.22KTurnover

21.62P/E Static

5.57P/B

0.00%Div Yield TTM

12.68%ROA

103.89052wk High

-0.01Volume Ratio

312.44MNet Profit

65.07MShares

4.2278EPS TTM

-0.04Beta

23.48%ROE

47.25052wk Low

2.96%Amplitude

61.20%Gross Margin

6.75BMarket Cap

5.32Reward/Risk

2.33%Risk Rate

TradingKey Stock Score of Lantheus Holdings Inc

Currency: USD Updated: 2026-06-22

Key Insights

Lantheus Holdings Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 1 out of 203 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 102.46.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lantheus Holdings Inc's Score

Industry at a Glance

Industry Ranking

1 / 203

Overall Ranking

38 / 4577

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Lantheus Holdings Inc Highlights

StrengthsRisks

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 18.91% year-on-year.

Overvalued

The company’s latest PE is 25.12, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 77.80M shares, decreasing 7.09% quarter-over-quarter.

Held by Private Capital

Star Investor Private Capital holds 273.79K shares of this stock.